Floatz logo

Seladelpar

Hyperlipidemia

Gilead SciencesSmall moleculePhase 2Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
39/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the Hyperlipidemia cohort.

Asset / SponsorPhaseRating
ATORVASTATIN
Poznan University of Medical Sciences
Phase 4BBB
Rosuvastatin
Nanjing First Hospital, Nanjing Medical University
Phase 4BBB
PRAVASTATIN
University of North Carolina, Chapel Hill
Phase 4BBB
Ezetimibe
NewAmsterdam Pharma
Phase 4BBB
Fenofibrate
Ospedale di Circolo - Fondazione Macchi
Phase 4BB

View all 35 →

Same molecule, other indications

Seladelpar is also rated in:

primary biliary cholangitisActive
BB
Indicative · Phase 3
68 / 100
View asset →
primary sclerosing cholangitisDormant
CCC
Indicative · Phase 2
52 / 100
View asset →
metabolic dysfunction-associated steatohepatitisDormant
CCC
Indicative · Phase 2
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →